AR037255A1 - Composiciones farmaceuticas que contienen oxibutinina - Google Patents
Composiciones farmaceuticas que contienen oxibutininaInfo
- Publication number
- AR037255A1 AR037255A1 ARP020104230A ARP020104230A AR037255A1 AR 037255 A1 AR037255 A1 AR 037255A1 AR P020104230 A ARP020104230 A AR P020104230A AR P020104230 A ARP020104230 A AR P020104230A AR 037255 A1 AR037255 A1 AR 037255A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- oxybutynin
- dosage form
- treatment
- incontinence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Abstract
Se provee una composición farmacéutica y una forma de dosificación para el tratamiento de la incontinencia con oxibutinina y una segunda droga. La segunda droga puede ser cualquier droga para el tratamiento de la incontinencia. Dependiendo de la vía de administración, la forma de dosificación empleada, y la segunda droga que se utilice, la forma de dosificación puede incluir independientemente cantidades terapéuticas o subterapéuticas de oxibutinina y de la segunda droga. Realizaciones particulares incluyen una forma de dosificación que provee una liberación controlada de oxibutinina y de la segunda droga para mantener los niveles terapéuticos efectivos de oxibutinina y/o la segunda droga en un mamífero por un período de tiempo extendido. Se provee un dispositivo osmótico que comprende un núcleo bicapa. El dispositivo osmótico provee una liberación controlada dual de ambas drogas desde el núcleo. Se provee un método para el tratamiento de la incontinencia urinaria (por estrés o urgencia) con una composición farmacéutica y una forma de dosificación. Juntas, la oxibutinina y la segunda droga proveen un beneficio clínico general mejorado con relación a cualquiera de los agentes administrados solos y aproximadamente en la misma dosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/992,488 US20030185882A1 (en) | 2001-11-06 | 2001-11-06 | Pharmaceutical compositions containing oxybutynin |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037255A1 true AR037255A1 (es) | 2004-11-03 |
Family
ID=25538393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104231A AR037256A1 (es) | 2001-11-06 | 2002-11-06 | Forma de dosificacion de liberacion controlada dual |
ARP020104230A AR037255A1 (es) | 2001-11-06 | 2002-11-06 | Composiciones farmaceuticas que contienen oxibutinina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104231A AR037256A1 (es) | 2001-11-06 | 2002-11-06 | Forma de dosificacion de liberacion controlada dual |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030185882A1 (es) |
EP (1) | EP1461018A2 (es) |
AR (2) | AR037256A1 (es) |
AU (2) | AU2002363361A1 (es) |
BR (1) | BR0213948A (es) |
UY (2) | UY27533A1 (es) |
WO (2) | WO2003039519A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
TW200302748A (en) * | 2002-02-01 | 2003-08-16 | Pfizer Prod Inc | Osmotic delivery system |
EP2087882A1 (en) * | 2002-03-26 | 2009-08-12 | Teva Pharmaceutical Industries Ltd. | Drug microparticles |
US20050175690A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms |
AR039744A1 (es) * | 2002-06-26 | 2005-03-09 | Alza Corp | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
JP2005536568A (ja) * | 2002-07-29 | 2005-12-02 | アルザ・コーポレーシヨン | トピラメートの調節分配用の調剤および投薬形態 |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20050271691A1 (en) * | 2003-02-21 | 2005-12-08 | Cardio Combos Llc | Prepackaged aqueous pharmaceutical formulations |
EP1653922A2 (en) * | 2003-08-06 | 2006-05-10 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
PT2210605T (pt) * | 2003-11-04 | 2017-04-24 | Tcd Royalty Sub Llc | Formas de dosagem única diária de tróspio |
US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
US20050175696A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
AU2004312084A1 (en) * | 2003-12-29 | 2005-07-21 | Alza Corporation, Inc. | Novel drug compositions and dosage forms of topiramate |
JP2007522249A (ja) * | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | 精神医学的状態の処置のための、nmdaレセプターアンタゴニストと、抗うつ薬であるmaoインヒビターまたはgadphインヒビターとの併用 |
WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
EP1629834A1 (en) * | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
BRPI0518506A2 (pt) | 2005-01-27 | 2008-12-02 | Alembic Ltd | tablete e formulaÇço de liberaÇço prolongada de levetiracetam |
NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
EP2032124A1 (en) * | 2006-06-27 | 2009-03-11 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
EP2175843B1 (en) * | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
WO2009052353A2 (en) * | 2007-10-17 | 2009-04-23 | Dr. Reddy's Laboratories Ltd. | Trospium pharmaceutical formulations |
WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
WO2011161504A1 (en) * | 2010-06-23 | 2011-12-29 | Micro Labs Limited | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
CN102048706B (zh) * | 2011-01-12 | 2012-02-22 | 山东创新药物研发有限公司 | 一种氢溴酸达非那新缓释片及制备方法 |
CN103156804A (zh) * | 2011-12-13 | 2013-06-19 | 重庆医药工业研究院有限责任公司 | 一种奥昔布宁透皮凝胶及其制备方法 |
ES2903149T3 (es) * | 2012-05-14 | 2022-03-31 | Shionogi & Co | Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado |
CN103127023B (zh) * | 2013-03-01 | 2014-08-27 | 河北天成药业股份有限公司 | 一种盐酸度洛西汀肠溶片及其制备方法 |
GB201708224D0 (en) * | 2017-05-23 | 2017-07-05 | Juniper Pharmaceuticals Uk Ltd | Device |
BR112020015316A2 (pt) * | 2018-01-30 | 2020-12-08 | Apnimed, Inc. (Delaware) | Métodos e composições para o tratamento da apneia do sono |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4309996A (en) * | 1980-04-28 | 1982-01-12 | Alza Corporation | System with microporous releasing diffusor |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
US4552880A (en) * | 1983-02-15 | 1985-11-12 | Merrell Dow Pharmaceuticals Inc. | Aroylimidazolones |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
US4661583A (en) * | 1985-06-24 | 1987-04-28 | Ashland Oil, Inc. | Reaction of bicyclic amide acetal with imide |
US4723957A (en) * | 1986-02-07 | 1988-02-09 | Alza Corp. | System for delivering drug with enhanced bioacceptability |
US4971790A (en) * | 1986-02-07 | 1990-11-20 | Alza Corporation | Dosage form for lessening irritation of mocusa |
US4867969A (en) * | 1986-02-07 | 1989-09-19 | Alza Corporation | Hydrogel formulation for administering non-steroidal drugs |
US4662880A (en) * | 1986-03-14 | 1987-05-05 | Alza Corporation | Pseudoephedrine, brompheniramine therapy |
US4863456A (en) * | 1986-04-30 | 1989-09-05 | Alza Corporation | Dosage form with improved delivery capability |
US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
WO1988001170A1 (en) * | 1986-08-20 | 1988-02-25 | Teikoku Seiyaku Co., Ltd. | Steroidal drug-containing preparation for external use |
US4765957A (en) * | 1986-12-29 | 1988-08-23 | Carondelet Foundry Company | Alloy resistant to seawater and other corrosive fluids |
DE3716260C1 (de) * | 1987-05-15 | 1988-07-28 | Dyckerhoff & Widmann Ag | Verfahren zur Justierung und Befestigung von Funktionsflaechen eines Fahrwegs einer elektromagnetischen Schnellbahn und Vorrichtung zur Durchfuehrung des Verfahrens |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
US4904474A (en) | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5006348A (en) * | 1990-05-04 | 1991-04-09 | Kraft General Foods, Inc. | Method for manufacture of swiss cheese |
ATE86440T1 (de) * | 1990-06-13 | 1993-03-15 | Manfred Oelsner | Verfahren zur herstellung von pektin- und zuckerhaltigen zubereitungen, wie konfituere, marmelade od.gdl. |
US5976571A (en) * | 1991-01-31 | 1999-11-02 | Port Systems, L.L.C. | Method for making a multi-stage drug delivery system |
US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5190765A (en) * | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
JP2646170B2 (ja) | 1992-06-24 | 1997-08-25 | 日本ヘキスト・マリオン・ルセル株式会社 | 徐放性塩酸オキシブチニン製剤 |
US5643155A (en) * | 1993-11-02 | 1997-07-01 | Kallassy; Charles | Aquatic exercise device |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
WO1996012477A1 (en) | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO1997016814A1 (en) | 1995-11-03 | 1997-05-09 | Sierra Semiconductor Corporation | Yuv video backend filter |
JP2665658B2 (ja) | 1995-12-18 | 1997-10-22 | 住友特殊金属株式会社 | 希土類・鉄・コバルト・ボロン系正方晶化合物 |
WO1997033566A2 (en) * | 1996-03-12 | 1997-09-18 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
ES2141044B1 (es) * | 1997-02-26 | 2001-02-01 | Alza Corp | Terapia con oxibutinina. |
US5866184A (en) * | 1997-03-12 | 1999-02-02 | World Class Packaging Systems, Inc. | Method of packaging a food product in a ventable package |
DE69818607T2 (de) * | 1997-05-30 | 2004-07-29 | Osmotica Corp. | Mehrlagige osmosevorrichtung |
SI1039882T1 (sl) | 1998-08-27 | 2011-01-31 | Pfizer Health Ab | Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem |
WO2000019997A1 (en) | 1998-10-07 | 2000-04-13 | Alza Corporation | Controlled release dosage from comprising oxybutynin |
US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
-
2001
- 2001-11-06 US US09/992,488 patent/US20030185882A1/en not_active Abandoned
-
2002
- 2002-11-06 EP EP02798241A patent/EP1461018A2/en not_active Withdrawn
- 2002-11-06 AR ARP020104231A patent/AR037256A1/es not_active Application Discontinuation
- 2002-11-06 AR ARP020104230A patent/AR037255A1/es not_active Application Discontinuation
- 2002-11-06 UY UY27533A patent/UY27533A1/es not_active Application Discontinuation
- 2002-11-06 BR BR0213948-0A patent/BR0213948A/pt not_active Application Discontinuation
- 2002-11-06 UY UY27532A patent/UY27532A1/es not_active Application Discontinuation
- 2002-11-06 AU AU2002363361A patent/AU2002363361A1/en not_active Abandoned
- 2002-11-06 AU AU2002363360A patent/AU2002363360A1/en not_active Abandoned
- 2002-11-06 WO PCT/CR2002/000006 patent/WO2003039519A2/es not_active Application Discontinuation
- 2002-11-06 WO PCT/CR2002/000007 patent/WO2003039436A2/es not_active Application Discontinuation
-
2005
- 2005-12-29 US US11/321,736 patent/US8241667B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
UY27532A1 (es) | 2003-05-30 |
US20060177510A1 (en) | 2006-08-10 |
WO2003039436A2 (es) | 2003-05-15 |
AU2002363361A1 (en) | 2003-05-19 |
UY27533A1 (es) | 2003-05-30 |
US20030185882A1 (en) | 2003-10-02 |
EP1461018A2 (en) | 2004-09-29 |
WO2003039436A3 (es) | 2004-02-26 |
WO2003039519A2 (es) | 2003-05-15 |
BR0213948A (pt) | 2004-08-31 |
AR037256A1 (es) | 2004-11-03 |
US8241667B2 (en) | 2012-08-14 |
AU2002363360A1 (en) | 2003-05-19 |
WO2003039519A3 (es) | 2004-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
ES2314200T3 (es) | Una combinacion de un antagonista de nmda e inhibidores de esterasa de acetilcolina par ael tratamiento de la enfermedad de alzheimer. | |
US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
ES2714550T3 (es) | Composiciones farmacéuticas y método para tratar la inflamación en ganado bovino y otros animales | |
ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
AR035533A1 (es) | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la | |
Koerber et al. | Coexistent psoriasis and bullous pemphigoid: a report of six cases | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
ES2564936T3 (es) | Aerosol nasal líquido que contiene naltrexona a dosis baja | |
CO5261582A1 (es) | Composiciones de valdecoxib | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
ES2323646T3 (es) | Uso de derivados de pirrol contra la ansiedad. | |
BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
Lowenstein et al. | Out-of-hospital treatment of status epilepticus and prolonged seizures. | |
ES2365387T3 (es) | Composiciones analgésicas y antiflamatorias que contienen celecoxib e ibuprofeno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |